EcoDrugPlus

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOTSG00005022632
Gene Symbol: HTR1E
1 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOTSG00005034726
Gene Symbol: HTR1E
1 Cross references
111 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOTSG00005009760
Gene Symbol: HTR1E
1 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1e

Ensembl ID : ENSOTSG00005021988
Gene Symbol: HTR1E
3 Cross references
139 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSOTSG00005010376
Gene Symbol: HTR1F
1 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOTSG00005010788
Gene Symbol: HTR2A
3 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOTSG00005010999
Gene Symbol: HTR2A
3 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSOTSG00005004999
Gene Symbol: HTR2A
3 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSOTSG00005028622
Gene Symbol: HTR2B
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b-Like

Ensembl ID : ENSOTSG00005006158
Gene Symbol: LOC112251984
3 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSOTSG00005021676
Gene Symbol: HTR2C
1 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSOTSG00005029079
Gene Symbol: HTR3A
1 Cross references
193 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).